Table 1.

Baseline Data (N = 126)

Variable	Total Sample
Sex, male	94 (74.60%)
Age, years	70.2 ± 2.9
Race
Caucasian	105 (83.3%)
African-American	16 (12.7%)
Other	5 (4.00%)
Income
Under $29,999	39 (35.8%)
$30,000 to $74,999	42 (38.5%)
$75,000 or more	28 (25.7%)
Employment status
Working (full- or part-time)	40 (31.8%)
Not employed/retired	86 (68.3%)
Body mass index, kg/m2	32.7 ± 5.5
Waist-to-hip ratio	0.99 ± 0.07
Neck circumference, cm	41.7 ± 3.9
Framingham RHI	0.51 ± 0.40
Systolic blood pressure, mmHg	128.2 ± 16.3
Diastolic blood pressure, mmHg	70.9 ± 8.9
Total cholesterol, mg/dL	157.8 ± 32.2
Low-density lipoprotein cholesterol, mg/dL	86.4 ± 24.5
High-density lipoprotein cholesterol (HDL-C), mg/dL	46.2 ± 13.1
Total cholesterol to HDL-C ratio	3.6 ± 0.8
Blood glucose, mg/dL	113.4 ± 32.0
Smoking status, yes	10 (11.6%)
Apnea hypopnea index, events/hr	26.4 ± 8.9
High sensitivity C-reactive protein, ug/mL	3.5 ± 5.7
Plasminogen activator inhibitor-1, ng/mL	42.8 ± 36.5
Hypertension diagnosis, yes	114 (90.5%)
Hyperlipidemia diagnosis, yes	113 (89.7%)
Diabetes, yes	52 (41.6%)
Percent of time with O2 sats < 90%	9.5 ± 13.2
Nitrate usage, yes	24 (19.5%)
Calcium channel blocker usage, yes	43 (34.1%)
Beta-blocker usage, yes	82 (65.1%)
Ace inhibitor usage, yes	90 (71.4%)
Statin usage, yes	117 (92.9%)
Diuretic usage, yes	50 (40.5%)
Peripheral dilator usage, yes	12 (9.5%)

Abbreviations: RHI, reactive hyperemia index

Data expressed as mean ± standard deviation or frequency (n) and percentage (%)